The platform has seen an overall growth of 84% in the number of people seeking consultations for skin-related issues
Second interchangeable biosimilar product approved by agency
Zydus' Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis .
Subscribe To Our Newsletter & Stay Updated
